कृपया अन्य खोज का प्रयास करें
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Chaim Hurvitz | 61 | - | Director |
Yafit Stark | 69 | 2008 | Clinical Development Strategy Advisor |
Yechezkel Barenholz | 83 | 2008 | Independent Director |
Moshe Salai | - | - | Member of Scientific Advisory Board |
Erez Kachel | - | - | Member of Scientific Advisory Board |
Hartzell V. Schaff | - | 2017 | Member of Scientific Advisory Board |
Robert Benjamin Stein | 73 | 2020 | Independent Director |
Dikla Czaczkes Akselbrad | 51 | 2014 | CEO & Director |
Itzhak Krinsky | 71 | 2019 | Independent Director |
Jacob Harel | 69 | 2017 | Independent Chairman |
Mitchel S. Berger | - | 2022 | Member of Scientific Advisory Board |
Joseph BenAmram | 60 | 2023 | Independent Director |
Nir Dror | 48 | 2020 | Independent Director |
Frederick Lang | - | 2021 | Member of Scientific Advisory Board |
Nurit Tweezer-Zaks | 58 | 2023 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है